JinkoSolar

Phase A — Understand the business

Lens 1 · Company Overview

JinkoSolar is the largest solar-module manufacturer on earth by shipment volume — 86.8 GW shipped in 2025, the seventh time it has held the global No. 1 sales rank . By end-2025 it had become the first manufacturer ever to cumulatively deliver over 390 GW of modules; its N-type Tiger Neo series alone has surpassed 220 GW cumulative and was >99% of 2025 shipments ``.

The business is a vertically integrated silicon-to-module manufacturer: it pulls mono ingots, slices wafers, makes cells, and assembles modules, selling ~95.5% of revenue as photovoltaic products (mostly own-brand "JinkoSolar" modules, a small OEM slice, plus surplus wafers/cells) and ~4.5% as other solar materials . It has bolted on an **energy-storage system (ESS)** business (launched 2022): 17 GWh of pack integration capacity and 5 GWh of battery-cell capacity by end-2025, and a BNEF "Tier 1" storage rating for Q1 2026 .

• Customers (Lens 1 contract structure): Over 8,700 customers across ~200 countries; utility-scale developers, EPC contractors, distributors, system integrators, distributed-generation buyers . **No single customer is >10% of revenue**; the largest *group* customer was 5.1% / 7.7% / **3.0%** of revenue in 2023/24/25, and the top-five group customers just **12.5%** in 2025 (down from 18.6%) — genuinely diversified demand .
• Payment terms: overseas customers generally pay within 90 days; domestic (China) customers pay 90–95% within 180 days, with a 1–2-year retainage until the customer's project runs normally ``. That is a long, credit-heavy working-capital cycle — a structural cash drag in a downturn.
• Corporate structure (critical): JKS (NYSE ADR) is a Cayman holdco whose principal operating subsidiary, Jiangxi Jinko (Jinko Solar Co., Ltd., 688223.SH), is separately listed on Shanghai's STAR Market (IPO Jan 2022). JKS owns ~55.6% of Jiangxi Jinko directly via its Hong Kong sub ``. This dual-listing is the single most important fact about the equity (see Lens 7 / Lens 11).

Lens 2 · Supply Chain — name the names

Upstream polysilicon → ingots/wafers (in-house) → cells (in-house) → modules (in-house) → global buyers.

• Polysilicon (the key input, single largest cost): sourced from a concentrated group. Top-5 group suppliers = 85.2% of silicon purchases in 2025 (83.1% / 81.8% prior years); the largest single group supplier was 28.8% . Named suppliers that are also **JinkoSolar equity-method affiliates**: **Xinte Silicon** (RMB234M of poly bought in 2025), **Sichuan Yongxiang** (RMB302M), and **Zhejiang New Materials** (RMB81M in Q4-25) — Jinko co-invested in Xinte and Sichuan Yongxiang in 2021 . So a slice of the poly supply chain is related-party (see Lens 10).
• Manufacturing footprint: >10 production bases globally; the flagship Shanxi Integrated Base (56 GW integrated wafer-cell-module, the industry's largest N-type integrated site) had Phase I (14 GW) and Phase II fully operational by end-2025 . **Overseas integrated capacity 14 GW, including 2 GW of N-type module capacity in the U.S.** and lines in Vietnam/Malaysia; a **Saudi Arabia JV** (with Renewable Energy Localization Co. + Vision Industries, signed Jul 2024) remains "at a preliminary stage" .
• Downstream chokepoints: the U.S. is the highest-value end market but the most policy-gated — AD/CVD orders, the First Solar TOPCon patent case, UFLPA. Domestic-China cash conversion is throttled by 180-day + retainage terms and PRC currency controls (87% of the group's ~RMB31.0B liquid assets sit inside China) ``.
• Capacity (Dec 31 2025): mono wafer 120 GW · cell 95 GW · module 130 GW — being *rationalized down* to ~100 GW integrated by end-2026 per guidance.

Lens 3 · Competitive Advantages (moats)

Jinko's moat is real but shallow and narrowing, which is the whole problem with the sector.

• Technology / IP (the strongest leg): industry-leading N-type TOPCon efficiency — mass-production cell efficiency 26.6% by end-2025 (vs ~26.2% 2024), a 27.79% lab record (Nov 2025), and a 34.76% perovskite-tandem breakthrough . It holds **3,559 granted patents including 1,484 TOPCon patents** — one of the world's largest TOPCon estates — plus 2,033 pending, backed by 2,184 R&D staff . Bankability/brand: No. 1 in Wood Mackenzie's 2025 module ranking, most-bankable in BNEF's 2024 survey, "AAA" in PV Tech's Q3-25 bankability report, MSCI ESG upgraded to A ``.
• Scale / cost: genuine cost leadership from vertical integration and the Shanxi mega-base. But scale is table stakes in solar — LONGi, Trina, JA Solar, Canadian Solar all have it.
• Why the moat is shallow: modules are a commodity. Bargaining power over customers is weak (no customer >3% — Jinko needs the buyers more than they need Jinko). Bargaining power over polysilicon suppliers is limited (85% concentrated, partly related-party). And TOPCon — 99% of shipments — is now so widely adopted that First Solar is suing the entire Chinese industry over the underlying patent (Lens 10). The efficiency lead is measured in tenths of a percent and resets every 18 months. Conclusion: a durable brand/bankability moat sitting on top of a commodity P&L — enough to be the last one standing, not enough to earn a through-cycle return.

Lens 4 · Segments

JinkoSolar reports one operating segment (vertically integrated solar manufacturing) per ASC 280 ``, so the only meaningful cuts are product and geography.

By product (2025): PV products 95.5% of revenue (RMB62.53B) · other solar materials 4.5% (RMB2.97B) . ESS is inside "PV products/other" and not yet separately material to revenue, though management guides ESS shipments to **more than double in 2026** .

By geography — net revenue, RMB thousands ``:

Trend & cause: every region fell in absolute RMB in 2025 on collapsing ASPs. The Americas roughly halved (RMB22.5B→12.3B) as U.S. AD/CVD and trade friction bit. China stayed ~34% of the mix but shrank with domestic price war. The wild Asia-Pacific/Rest-of-world swings (AsiaPac 1.9%→20.5%, RoW 25.1%→13.1%) look like Middle East/Saudi reclassification between buckets year-to-year — treat the sub-region deltas with caution, not the totals. ~65.5% of revenue is ex-China / foreign-currency ``.

---

Phase B — Measure performance

Lens 5 · Earnings Result (FY2025 — the crisis print)

This is a catastrophe year masked by an accounting cushion. Full P&L, RMB thousands with % of revenue ``:

Read this carefully:

• Revenue −29.0% (2024 was already −22.3%) — two straight years of top-line collapse, entirely ASP-driven. Volume fell only 6.5% (92.9→86.8 GW), so the ~RMB27B revenue loss is almost pure price. Blended PV ASP fell from ~RMB1.48/W (2023) → ~RMB0.97/W (2024) → ~RMB0.72/W (2025) ``.
• Gross margin imploded 16.0% → 10.9% → 2.2%. In Q4-2025 gross margin was reportedly just 0.3% `` — i.e. Jinko was selling modules at cash cost.
• Operating loss RMB8.9B (−13.6% margin), deepened by a RMB1.66B (US$237.7M) long-lived-asset impairment (equipment obsolescence as old lines are scrapped) ``.
• Two cushions turned a −RMB8.9B operating loss into a "only" −RMB4.45B loss to ADR holders: (1) an income-tax BENEFIT of RMB2.22B (US$317.6M), and (2) minority holders of Jiangxi Jinko absorbed RMB2.75B (US$393M) of the loss — because the STAR-listed sub is only ~56% owned. The headline US$(12.20) loss per ADS would have been far worse on a whole-company basis.
• Government subsidy income RMB1.15B (US$164M, 1.8% of revenue) and net FX props are recurring bottom-line supports worth watching ``.
• No going-concern qualification. Management asserts cash + operations + credit facilities are sufficient for ≥12 months — a defensible claim given RMB22.9B cash+restricted and RMB48.0B undrawn facilities ``.

Q1-2026 update (the inflection tell) ``: shipments 13.7 GW (−45% QoQ, −22% YoY — deliberate volume restraint); revenue RMB12.25B (US$1.78B, −11.5% YoY); gross margin recovered to 8.3% (from 0.3% in Q4-25 and a −2.5% gross loss in Q1-25); net loss narrowed to RMB463.5M (US$67.2M); cumulative shipments passed 400 GW. FY26 guidance: 75–85 GW modules, Q2 14–16 GW, capacity cut to ~100 GW by year-end, ESS to more than double. The margin snap-back is the first hard evidence the cycle may be bottoming.

Lens 6 · Earnings Calls (sentiment trend)

No transcripts on the shelf (transcripts/ empty); this lens is ``-only and thinner than ideal — flag for backfill.

• Tonal arc 2024→2026: management moved from "weathering oversupply / defending share" (2024) to explicit self-restraint — reaffirming a lower FY26 shipment band (75–85 GW, below the 86.8 GW actually shipped in 2025) and cutting nameplate capacity from 130→100 GW . The recurring themes are **(1) high-efficiency/high-power mix** ("over 60% high-efficiency products"), **(2) ESS as the growth pivot** (guided to >2x), and **(3) margin over volume**. The thing they *stopped* saying: aggressive capacity-expansion targets. Q1-26 framing — "record cumulative shipments, margins surging despite shipment decline" — is management leaning into the **discipline narrative** . Directionally credible but self-serving; verify against the actual transcript before relying on it.

Lens 7 · Comps

Peers are mostly loss-making commodity cyclicals, so P/E is meaningless and P/B / P/S carry the weight. Multiples ``, dated; do not treat as precise:

Sources: JKS US$15.72, P/B 0.36 ; FSLR cap/rev/NI ; CSIQ ; Jiangxi Jinko cap .

The comp that matters: JinkoSolar ships ~4x First Solar's volume and is the world No. 1, yet its ADR market cap (US$0.82B) is ~1/36th of First Solar's (US$29.7B) and below Canadian Solar's. The market is pricing profit and jurisdiction, not gigawatts. First Solar's US CdTe margins are protected by the IRA and by the very TOPCon patent it is now wielding against Jinko — the cleanest expression of "the value in solar accrued to the policy-protected Western incumbent, not the volume king." P/B 0.36 is the anchor: JKS trades at ~⅓ of stated book.

Lens 8 · Stock-Price Catalysts (what actually moves JKS)

``, pattern over ~5 years:

• 2020 — Bonitas short report (Mar 4, 2020): alleged "fake sales and profits" and value-destroying related-party deals; Jinko denied and announced a US$100M buyback. Stock was volatile but the report never produced an SEC action (Lens 10) ``.
• 2021–22 — the boom: N-type Tiger Neo launch + the Jiangxi Jinko STAR IPO (Jan 2022) unlocked a domestic-market valuation for the operating sub; Jiangxi Jinko peaked at ~CNY105B cap ``.
• 2023–25 — the bust: the price war. Polysilicon RMB230k/ton (2022) → ~RMB30/kg (Apr 2026); module ASP down ~60%; JKS from ~US$32 to ~US$15 ``.
• 2024 — Shanxi fire (Apr 26, 2024): a wafer-slicing/cell workshop fire, "material impact" on 2024 results ``.
• 2025–26 — policy hope vs. policy stall: China's "anti-involution" campaign (launched Jul 1, 2025) and a proposed CNY 50B capacity-retirement fund lifted sentiment; the stock then round-tripped when SAMR halted the ~US$7B polysilicon-consolidation plan in Jan 2026 ``.
• What the tape reveals: JKS trades on (1) the China supply-cut narrative (poly prices, "anti-involution" headlines), (2) US trade policy (AD/CVD, Section 201, the First Solar case), and (3) the Jiangxi Jinko A-share — not on Jinko's own earnings beats. It is a macro/policy option on the solar cycle, not a fundamentals-driven equity.

---

Phase C — Judge people & books

Lens 9 · Management

• Xiande Li, 50 — Founder, Chairman & CEO. He simultaneously chairs all three listed Jinko entities: JKS (NYSE), Jiangxi Jinko / Jinko Solar Co. (688223.SH, STAR), and Jinko Power (601778.SH), the downstream developer ``. This tri-entity control is the central governance fact.
• Track record: built JinkoSolar from a 2006 startup into the world's No. 1 module maker (390+ GW cumulative) and survived the 2011–13 solar shakeout that killed Suntech and LDK — the 20-F itself notes net losses "in each quarter from Q4-2011 to Q1-2013" ``. Proven cycle-survivor and share-taker.
• Skin in the game: insiders own 27.3% of ordinary shares; Xiande Li 21.0% (via Brilliant Win Holdings, 20.0%), with a June-2021 acting-in-concert agreement binding Xiande Li + Kangping Chen (Yale Pride, 8.1%) + Xianhua Li (5.2%) — a ~34% founder concert bloc . Cash comp is nominal (RMB8.9M / US$1.3M total for all execs+directors in 2025), typical of founder-controlled PRC issuers .
• Capital allocation: aggressive counter-cyclical reinvestment (capex RMB15.85B in 2023) sharply reversed to RMB3.30B in 2025 — disciplined retrenchment. Notably, Jinko kept paying a dividend through the loss year (US$78.7M Dec-23, US$76.8M Aug-24, US$68.1M Jul-25) `` — a confidence signal, or founder-friendly cash extraction from a company that just lost RMB4.5B; reasonable people read it both ways.
• Red flags: the founder-controls-both-sides related-party web (sales to Jinko Power, poly bought from co-owned Xinte/Sichuan Yongxiang) is a permanent governance overhang, and was the core of the 2020 Bonitas thesis (Lens 10/13). Archetype: dominant founder-operator — a strength for surviving a brutal cycle, a risk for minority ADR holders whose interests may rank behind the A-share and the founder's other vehicles.
• Board adds credible independents: Steven Markscheid, Gang Chu (ex-CICC COO, since Aug 2024), Wing Keong Siew. CFO Mengmeng (Pan) Li, 45.

Lens 10 · Forensic Red Flags

Accounting-risk map `` unless noted:

• Revenue recognition / receivables: long domestic terms (180 days + 1–2yr retainage) inflate receivables; third-party AR RMB13.41B (US$1.92B), roughly flat YoY even as revenue fell 29% — i.e. AR/revenue rose (DSO stretching). Watch credit-loss provisioning.
• Inventory: rose to RMB14.48B (US$2.07B) from RMB12.51B while revenue fell 29% and prices fell — management calls it "planned stockpiling of raw materials" (buying cheap poly), but rising inventory into falling prices is a classic write-down setup. FY25 already carried inventory write-downs inside the 2.2% gross margin.
• Non-controlling interests as a loss shock-absorber: RMB2.75B of the 2025 loss was pushed to Jiangxi Jinko minorities — legitimate under the structure, but it flatters the ADR-level loss and complicates like-for-like comparison.
• Below-the-line props: RMB1.15B subsidy income + a RMB2.22B tax benefit did the heavy lifting between the operating loss and the reported loss — low-quality earnings support.
• Related-party transactions (the recurring flag): sales to Jinko Power (RMB44M in 2025, down from RMB353M); poly procurement from equity-method affiliates Xinte Silicon (RMB234M), Sichuan Yongxiang (RMB302M), Zhejiang New Materials (RMB81M); balances "interest-free, not collateralized, no definitive repayment terms" ``.
• Pledged assets / leverage: RMB13.28B of PP&E, plus land/inventory/AR/deposits, pledged against RMB10.33B of borrowings — encumbered balance sheet.

Regulatory findings (required):

• SEC: regulatory/regulatory-findings.md records zero SEC Litigation Releases and zero AAERs naming JinkoSolar (EDGAR EFTS, 2021-07-10→2026-07-10) . The 2020 **Bonitas Research** short report (fake-sales / related-party value-stripping allegations, incl. the claim that Jinko Power was sold to Chairman Li in 2016 at a ~40% discount to a near-contemporaneous appraisal) **never resulted in an SEC enforcement action**; Jinko denied it . Treat as unproven but structurally live — the governance pattern it flagged still exists in the 2025 filing.
• Trade / IP enforcement (material):
• First Solar Section 337 ITC case (Inv. 337-TA-1494): filed Feb 24 2026, instituted Mar 26 2026; alleges Jinko + 9 others (Canadian Solar, JA Solar, Hanwha QCells, Trina, Runergy, etc.) infringe First Solar's US Patent 9,130,074 (TOPCon). First Solar seeks a general exclusion order that could bar infringing TOPCon imports into the U.S. regardless of maker . TOPCon is 99% of Jinko's shipments — this is the single biggest legal overhang. No liability accrued; discovery stage; ITC final determinations typically land ~16–18 months out (≈ late-2027).
• US AD/CVD: DOC AD/CVD on China cells/modules since 2011; June-2025 final AD/CVD duty orders on cells from Cambodia/Malaysia/Thailand/Vietnam closed the Southeast-Asia re-export backdoor; Section 201 cell tariffs expired Feb 2026; Jordan AD probe (Apr 2025) ongoing ``.
• UFLPA / forced-labor: US Uyghur Forced Labor Prevention Act creates detention risk for China-linked polysilicon — a standing compliance cost driving the overseas/US manufacturing build-out ``.
• HFCAA / delisting: ADSs could be barred from US trading if the PCAOB again loses access to inspect PRC auditors (the Dec-2021 determination was resolved in Dec-2022, but the risk is structurally live) ``.
• Litigation resolved: the Singapore-customer arbitration (365,000 modules deemed defective, 2012/13 contracts) settled Aug 2024 for US$31M, concluded ``.
• Bottom line: clean on SEC accounting enforcement; the live risks are trade/IP (First Solar GEO) and governance (related-party web), not a smoking-gun fraud.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection (EPS, next three fiscal years — FY2026/27/28)

Bottom-up, per-ADS, US$, from FY25 actuals + Q1-26 + guidance. Loss-per-ADS FY25 was US$(12.20); the swing factor is ASP × utilization, not volume. All outputs ``; no forecast.ts logged (watchlist rule).

Inputs: FY26 shipments ~80 GW (guidance mid) ; blended module ASP is the entire variable. FY25 gross margin 2.2%; Q1-26 already 8.3% . ~52.1M ADS ``.

• Base (US$/ADS): FY26 ≈ (1.50) — gross margin recovers to ~7–8% for the year (Q1 run-rate holds) but opex ~14–16% of a smaller revenue base keeps operations loss-making; ESS grows but is small; tax benefit + subsidy + NCI-absorption again cushion. FY27 ≈ (0.20) — approaching operating breakeven as China supply discipline lifts ASP toward ~RMB0.80–0.85/W. FY28 ≈ +1.50 — first clean profit if the cycle has turned and the US patent overhang is bounded. Arithmetic: FY26 rev ~US$8.0B (80 GW × ~US$0.10/W blended) × ~7.5% GM = ~US$0.6B gross − ~US$1.2B opex = ~−US$0.6B op loss; +~US$0.3B tax/subsidy +~US$0.2B NCI-absorbed → ~−US$0.08B to ADR ÷ 52.1M ≈ −US$1.5.
• Bull (US$/ADS): FY26 ≈ (0.30), FY27 ≈ +2.50, FY28 ≈ +5.00 — China enforces real capacity cuts, ASP recovers to ~$0.12/W+, gross margin back to ~12–14%, First Solar case settles with a bounded royalty. This is the "2016-style supply reform works" path.
• Bear (US$/ADS): FY26 ≈ (4.00), FY27 ≈ (3.50), FY28 ≈ (2.50) — price war persists (SAMR keeps blocking consolidation), inventory write-downs recur, First Solar wins a general exclusion order locking Jinko out of the US, and a fresh impairment cycle hits. Book value erodes toward the market's 0.36x P/B.

Verdict on the projection: the distribution is bimodal and policy-determined. There is no "muddle-through" base worth much — it hinges on whether Beijing forces supply out. Consensus (4–5 analysts, "Hold," avg target ~US$24.80–25.25, range US$20–28.50) implies ~60% upside to a ~US$25 handle but with a Hold rating — i.e. the Street sees the option value but won't underwrite the timing ``.

Lens 12 · Bull vs Bear

Bull case. The last man standing in a consolidating oligopoly. Jinko is No. 1 by volume, best-in-class on TOPCon efficiency/bankability, has RMB22.9B cash + RMB48B undrawn facilities, no going-concern flag, and just printed Q1-26 gross margin of 8.3% — the cycle is bottoming. It survived 2011–13; it will survive this. And the kicker: its ~56% stake in STAR-listed Jiangxi Jinko is worth ~US$5.4B against a US$0.82B ADR — you are buying the world's largest solar company at ~0.36x book and a huge holdco discount, with free upside from (a) the China supply-cut catalyst and (b) any narrowing of that discount.

Bear case (2–3 permanent-impairment risks). (1) The price war never ends — SAMR already killed the US$7B consolidation plan; if Beijing keeps prioritizing energy security/employment over margins, ASPs stay near cash cost and Jinko bleeds book value indefinitely. (2) US market access is legally severed — a First Solar general exclusion order would bar Jinko's TOPCon (99% of mix) from the highest-margin market. (3) The value never reaches the ADR — the A-share stake is trapped behind PRC capital controls, dividend restrictions (89% of net assets are inside restricted PRC subs), the founder's competing vehicles, and HFCAA delisting risk; the discount is rational, not an anomaly.

Pre-mortem (it's Jan 2028, the thesis broke): China refused to enforce capacity cuts through 2027, module ASPs never recovered, Jinko booked a third straight loss and a fresh impairment, the First Solar ITC case produced an exclusion order, and the A-share bubble deflated toward book — so the "hidden US$5B stake" shrank to US$2B and the holdco discount stayed wide because minorities still can't touch it. The ADR halved again.

Are multiples too high? No — 0.09x sales / 0.36x book is distress pricing. The risk isn't the multiple; it's that book value itself is impaired in the bear case (write-downs) and unreachable in the base case.

Contrarian view (what the market refuses to see): the market treats JKS as a dying commodity ADR and ignores that it is a cheap, liquid, USD-denominated call option on Chinese solar supply discipline + on the Jiangxi Jinko A-share — with a real cyclical bottom now visibly forming (8.3% GM). If Beijing does a 2016-style supply reform, this is a multi-bagger from US$15. The market is refusing to price the option, only the corpse.

Lens 13 · Devil's Advocate (short-seller)

• How the business structurally breaks: modules are a commodity with a permanent Chinese oversupply (570–600k MT of poly inventory = ~300 GW latent supply; utilization 40–80%). There is no pricing power and no path to it while capacity exceeds demand by ~2x. A "moat" of 0.4% efficiency and a brand award does not earn a return on a commodity.
• Concentration risk: not customer concentration (well-diversified) but jurisdiction concentration — the entire industry depends on China not blinking on subsidies/energy-security, and on the US not slamming the door. Both are outside Jinko's control.
• The dangerous competitor bulls underestimate: First Solar — not on the tape (thin-film, different tech) but in the courtroom. It has turned its balance sheet and IRA-protected US margins into a legal weapon (the 337 case) that can exclude Jinko from the US entirely. That is a more lethal threat than any Chinese rival.
• Worst capital-allocation / governance moves: the founder controls three listed entities that transact with each other; poly is bought from co-owned suppliers; a dividend was paid through a RMB4.5B loss year; the 2020 Bonitas report alleged the founder bought Jinko Power at a ~40% discount. None proven, but the pattern means ADR minorities sit at the back of the queue.
• What must hold for today's price: that book value is real and not about to be impaired, and that the China supply cut arrives before the cash cushion and A-share bubble deflate. If FY26 shipments/ASP disappoint by 20–30%, gross margin flips back toward zero and the "bottom" narrative dies.
• Single permanent-impairment scenario: First Solar wins a general exclusion order and the A-share deflates — Jinko loses its best market and its hidden asset simultaneously. Plausibility: moderate. The ITC case is the higher-probability leg.

Lens 14 · Management Questions (ordered by information value)

1. What is your realistic view on when Chinese module ASPs sustainably exceed all-in cash cost, and what specifically has to happen on capacity for that — given SAMR just blocked the polysilicon-consolidation plan?
2. On the First Solar Section 337 case: what is your defense to US Patent 9,130,074, and what is your contingency if the ITC issues a general exclusion order covering TOPCon?
3. Given your ~56% stake in STAR-listed Jiangxi Jinko is worth far more than JKS's entire ADR market cap, what will management do to close that discount for ADR holders — and is a value-unlock (special dividend, buyback, restructuring) on the table?
4. Why did you pay a US$68M dividend in a year you lost RMB4.5B — and how do you weigh that against the ADR discount to book?
5. How should ADR minorities think about the related-party arrangements (sales to Jinko Power, polysilicon from co-owned Xinte/Sichuan Yongxiang) and the governance guardrails around them?
6. What gross-margin trajectory should we expect for the rest of 2026 after the 8.3% Q1 print — is that the run-rate or a mix/one-off?
7. You cut nameplate capacity from 130→100 GW — is that the floor, or does discipline go further, and how do you avoid ceding share to LONGi/Trina/JA?
8. How large and how profitable can ESS realistically be by 2028, and what capital does it need?
9. What is the true utilization across wafer/cell/module today, and the cash-cost breakeven ASP at that utilization?
10. How much of the RMB14.5B inventory is finished modules vs. raw poly, and what write-down risk sits in it at current prices?
11. What is the plan for the US 2 GW module line and Saudi JV under UFLPA/AD-CVD/FEOC rules — is US manufacturing scalable or a hedge?
12. How exposed are you to HFCAA re-triggering, and what is the auditor-inspection status?
13. What are the covenants and refinancing schedule on the RMB28.9B of borrowings, and stress-tolerance if the loss persists into 2027?
14. What is the perovskite-tandem (34.76% lab) commercialization timeline, and does the XtalPi AI partnership change it?
15. Under what scenario would you stop paying the dividend and redirect that cash?

---